1 / 55

Pulmonary Thromboembolism

Pulmonary Thromboembolism. Emily S. Southward DVM University of Missouri – Columbia Veterinary Medical Teaching Hospital. Definition. Pulmonary thromboembolism One clot or many clots that form at distant sites and lodge in the pulmonary vasculature. Pulmonary artery thrombus

jacob
Télécharger la présentation

Pulmonary Thromboembolism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary Thromboembolism Emily S. Southward DVM University of Missouri – Columbia Veterinary Medical Teaching Hospital

  2. Definition • Pulmonary thromboembolism • One clot or many clots that form at distant sites and lodge in the pulmonary vasculature. • Pulmonary artery thrombus • Clots that form in the pulmonary vasculature. • Clots can partially or fully occlude pulmonary vessels.

  3. Virchow’s Triad • Venous stasis. • Injury or abnormalities to the vessel wall. • Alterations in coagulation properties.

  4. Venous Stasis • Accumlation of activated procoagulants. • Immobilization • Inadequate cardiac pump. • Promotes thrombus formation.

  5. Vessel Wall Injury • Acute or chronic injury to vessel endothelium. • Leads to activation of platelets and clotting cascade. • Promotes thrombus formation.

  6. Vessel Injury

  7. Platelet Adhesion

  8. Aggregation

  9. Alternations in Coagulation • Increase in procoagulant factors. • By trauma to vascular wall or extravascular tissues. • Releases tissue thromboplastin and phospholipid. • Leads to formation of prothrombin activator. • Prothrombin  Thrombin

  10. Alterations in Coagulation • Decrease in anticoagulant factors. • Thrombomodulin • Antithrombin III • Heparin • Alpha2-Marcoglobulin • Plasmin • Leads to hypercoagulable state by formation of thrombin.

  11. Thrombosis Formation • Platelet nidus at site of injury. • Growth by aggregation of platelets and fibrin. • Activation of clotting cascade. • Larger growth to a red fibrin thrombus. • Thrombus fractures and embolizes to other areas of the body.

  12. Predisposing Factors or Diseases for Development of PTE • Hypercoagulable state • Nephrotic syndrome • Immobilization • Amyloidosis • Early DIC • Hyperadrenocorticism • Capillary fragility • Activation of clotting cascade.

  13. Predisposing Factors or Diseases for Development of PTE • Hypercoagulable state • Capillary fragility • Diabetes Mellitus • Immune–mediated hemolyitc anemia • Sepsis • Hyperadrenocorticism • Activation of clotting cascade.

  14. Predisposing Factors or Diseases for Development of PTE • Hypercoagulable state • Capillary fragility • Activation of clotting cascade. • Sepsis • Pneumonia/pyothorax • Heartworm disease • Surgery • Bacterial endocarditis • Neoplasia

  15. Consequences of PTE • Respiratory. • Increased alveolar dead space. • Hyperventilation. • Hypoxemia. • Ventilation/perfusion inequality. • Intrapulmonary shunts.

  16. Normal Alveolus

  17. Increased Alveolar Dead Space

  18. Hypoxemia • Results from ventilation-perfusion inequality, physiologic shunting and increased dead space.

  19. Intrapulmonary Shunts • Blood that has not been to areas of ventilated lung and enters systemic circulation without gas exchange taking place. • Poorly oxygenated blood enters the arterial system lowering the PaO2. • Not responsive to oxygen therapy.

  20. Ventilation/Perfusion Inequality • V/Q inequality occurs when distribution of blood is altered to the alveoli. • O2 increase in the alveoli and CO2 decreases.

  21. Hemodynamic Changes • Increase in pulmonary vascular resistance. • Increased afterload to the right heart. • Can lead to circulatory collapse and shock.

  22. Clinical Signs • Not pathognomonic. • Dyspnea. • Tachypnea. • Hemoptysis. • Tachycardia. • Hypoxemia. • Sudden death.

  23. Diagnosis • CBC/Biochemistry results reflect primary disease process. • Hypoxemia common but 10% of patients are normal. • Thoracic radiographs can be normal and inconclusive.

  24. LaRue MJ and Murtaugh RJ. Pulmonary Thromboembolism in Dogs:47 cases (1986-87). J Amer Vet Med Assoc. 1990 Nov. 15;197(1):1368-1372. • Johnson LR et al. Pulmonary Thromboembolism in 29 dogs:1985-1995 J Vet Intern Med. 1999 Jul;13(4):338-345. • Flükiger MA and Gomez JA. Radiographic Findings in Dogs with Spontaneous Pulmonary Thrombosis or Embolism. Veterinary Radiology, Vol.25,No.3 124-131.

  25. Advanced Diagnostics • Pulmonary scintigraphy • Pulmonary angiography.

  26. Pulmonary Scintigraphy • Noninvasive • Aids in diagnosis of PTE but not definitive. • Two types- ventilation and perfusion scans.

  27. Performed first. Normal study rules out PTE. Radionuclide-labelled, macroaggregated albumin in peripheral vein. Perfusion Scan

  28. Inhaled radioactive inert gas-senon-133 or technetium-99m. Patient under general anesthesia. Normal in PTE. Ventilation Scan

  29. With PTE the ventilation scan would be normal and the perfusion scan abnormal. Suggestive of PTE.F Picture from WWW.bschsys.org/DiagnositcImaging/nucmd/htm Ventilation/Perfusion Combo

  30. Normal Human Perfusion Scan

  31. Abnormal Human Perfusion Scan

  32. Pulmonary Angiography • Performed if definitive diagnosis or exclusion of PTE is required. • Requires sedation or general anesthesia. • Greater risks. • Intraluminal filling defect and sharp cutoff are diagnostic for PTE.

  33. Human lung. Arrow indicates abrupt termination of a pulmonary artery. Www.brighamrad.Harvard.edu/cases/bwh/images. Pulmonary Embolus

  34. Treatment • Oxygen therapy. • Heparinization 200-300 units/kg subcutaneously every 8 hours. • Streptokinase or TPA. • Mechanical ventilation. • Long term- warfarin therapy.

  35. Monitoring • Clotting times- want to maintain PTT at 1.5-2.5 times normal or and ACT at 1.2-1.4 times normal. • Serial arterial blood gas analysis. • Respiratory rate. • Central venous pressure. • All other basic monitoring.

  36. Complications Of Therapy • Hemorrhage most common. • Not predictable. • Protamine therapy indicated with hemorrhage due to heparin. • Vitamin K or fresh-frozen plasma in warfarin therapy.

  37. Prognosis • Guarded. • Improves with early detection and treatment. • Improves each day the patient survives. • At risk for more emboli.

  38. UMC VMTH Cases • Three in data base. • Sadie • Magnum • Koko

  39. Sadie Bailey • 8-year-old FS mixed breed dog. • Presented for weight loss, anemia, and anorexia. • Weak and lethargic on presentation • Hemoabdomen, thrombocytopenia, and neutrophilia with left shift. • Developed severe dyspnea and ventricular tachycardia.

  40. Sadie’s Thoracic Films

  41. Sadie’s Thoracic Films

  42. Sadie’s Necropsy • Hepatocellular carcinoma • Adrenocortical hyperplasia • Pulmonary thrombois – most lobar branches effected. • Renal infarction.

  43. Magnum Meeks • 8-year-old MC doberman pinscher • Presented for dyspnea of two days duration. • Protein losing nephropathy.

  44. Magnum’s Thoracic Films

  45. Magnum’s Thoracic Films

  46. Koko Westerhoff • 12-year-old FS dachshund. • Presented for lethargy, anorexia, tachypnea, and possible CHF. • History includes diabetes mellitus, IVDD and cataracts. • PE- Increased BV lung sounds, mild crackles, tachycardia, and left systolic murmur.

  47. Koko’s Thoracic Films

  48. Koko’s Thoracic Films

More Related